Trial Profile
Randomized Phase II Trial of Adjuvant Combined Epigenetic Therapy With 5-azacitidine and Entinostat in Resected Stage I Non-small Cell Lung Cancer Versus Standard Care
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 07 Feb 2019
Price :
$35
*
At a glance
- Drugs Azacitidine (Primary) ; Entinostat (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- 08 May 2013 New source identified and integrated (University of Southern California Norris Comprehensive Cancer Center; 2N11-3).
- 01 May 2013 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.
- 13 Feb 2013 New source identified and integrated (Vanderbilt University Institutional Review Board; 120153).